KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Investing Activities: 2017-2024

Historic Cash from Investing Activities for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$159,000.

  • Aquestive Therapeutics' Cash from Investing Activities fell 193.75% to -$235,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$492,000, marking a year-over-year decrease of 207.50%. This contributed to the annual value of -$159,000 for FY2024, which is 84.02% up from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Cash from Investing Activities is -$159,000, which was up 84.02% from -$995,000 recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Cash from Investing Activities ranged from a high of -$159,000 in FY2024 and a low of -$2.5 million during FY2022.
  • Its 3-year average for Cash from Investing Activities is -$1.2 million, with a median of -$995,000 in 2023.
  • In the last 5 years, Aquestive Therapeutics' Cash from Investing Activities tumbled by 176.45% in 2022 and then spiked by 84.02% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Investing Activities (Yearly) stood at -$517,000 in 2020, then slumped by 76.60% to -$913,000 in 2021, then tumbled by 176.45% to -$2.5 million in 2022, then soared by 60.58% to -$995,000 in 2023, then surged by 84.02% to -$159,000 in 2024.